The short answer
Ulthera, also called Ultherapy or microfocused ultrasound with visualization (MFU-V), is designed to create small thermal-coagulation points at selected tissue depths. Most published clinical studies report temporary tenderness, redness, swelling, bruising or altered sensation rather than lasting tissue loss. Subcutaneous atrophy, neurological symptoms, burns and scarring have nevertheless appeared in case literature and post-market reports.
Those two facts can coexist. A rare or underreported complication may not appear in a small clinical trial, while a database built from voluntary reports can identify a signal without giving a reliable complication rate.
What Ulthera is intended to target
Ulthera focuses ultrasound energy below the skin surface at depths chosen by the operator. Its real-time imaging is intended to show tissue layers and coupling so energy can be placed in the planned plane. The aesthetic aim is controlled thermal injury followed by collagen remodelling and tissue contraction — not indiscriminate destruction of facial fat.
US FDA clearance describes specific indications and does not mean that every treatment area, depth or technique is appropriate. It is also not evidence of Thai FDA authorization for a particular machine. Device authenticity, local registration, operator training and a patient-specific treatment map remain separate checks.
What the evidence actually shows
A 2025 systematic review looked at 19 published studies covering 506 MFU-V patients and also searched the US FDA's MAUDE post-market database. The scientific literature contained one reported case of subcutaneous atrophy; significant events were otherwise limited. In 106 MAUDE records, lipoatrophy, neurological symptoms and scarring were among the more frequently described problems.
MAUDE is a warning-signal system, not a clinical trial. Reports can be incomplete, duplicated, unverified or influenced by how widely a device is used. There is no reliable denominator showing how many total treatments occurred, so those records cannot tell us the percentage of patients affected or prove causation in every case.
A separate meta-analysis of 42 MFU-V studies found that the commonly reported adverse effects were mild-to-moderate redness, swelling, bruising and tenderness. It did not find long-term nerve or muscle dysfunction, scarring or pigment damage in the included clinical studies. However, clinical studies often involve selected patients, trained investigators and limited follow-up; their reassuring results do not erase credible post-market concerns.
Why a face may look more hollow
A new hollow or contour change after treatment deserves attention, but appearance alone does not establish its cause. Possibilities include true subcutaneous atrophy, the resolution of early swelling, a change in lighting or camera angle, weight change, normal age-related volume loss, or a lifting effect that reveals pre-existing hollows differently.
This is why standardized photographs taken before treatment matter. A doctor assessing a concern should know the device, treatment date, areas mapped, cartridges or depths used, symptoms during treatment and the timeline of the change. Dismissing every concern as ageing is not responsible; diagnosing device-related fat loss from one selfie is not responsible either.
Why anatomy and technique matter
Ultrasound energy acts where it is focused, so facial anatomy, tissue thickness, treatment placement, coupling and selected depth matter. Real-time visualization can help the operator identify the intended tissue plane and avoid poor coupling, but it is a safety tool rather than a guarantee.
Operator training matters for mapping around nerves, vessels, bone and thin soft-tissue areas. Patient selection matters too: a plan intended for someone with substantial laxity may not make sense for a very lean face where volume preservation is a priority. These principles reduce avoidable risk but do not prove that every reported complication resulted from incorrect technique.
Expected effects and red flags
Usually temporary: tenderness, mild swelling, redness, bruising, tingling or small areas of altered sensation that steadily improve. The trend matters more than a rigid calendar.
Needs prompt clinical review:
- Severe, electric or increasing pain rather than settling soreness
- Blistering, welts, crusting, broken skin or a visible burn pattern
- New weakness, eyebrow or smile asymmetry, drooping or persistent numbness
- A new hollow, dent or contour change that persists or becomes more obvious
- Spreading redness, warmth, discharge, fever or another sign of infection
- Eye pain, vision change or other eye symptoms
Questions before treatment
- Is the machine genuine Ulthera, and can I see the model and treatment record?
- Who will perform the procedure, and what training do they have with this device?
- What tissue problem are you trying to change in my face?
- How will you map thin areas, existing hollows and important anatomy?
- How does real-time imaging change the plan during treatment?
- What symptoms should make me contact you immediately?
- How will an unexpected contour or nerve symptom be assessed and documented?
What to do if you are concerned
Contact the treating doctor and ask for an in-person assessment. Keep dated photographs in consistent lighting and obtain the treatment record, including machine, areas and transducers used. If symptoms are severe, worsening, involve weakness or vision, or the original provider is not responding, seek timely assessment from another licensed physician. Do not try to “replace” suspected volume loss with an immediate filler or repeat an energy treatment before the cause and tissue condition are assessed.
The bottom line
Lasting facial fat loss after Ulthera appears uncommon in published studies, but it has been reported and should not be dismissed. Post-market reports raise a real safety signal while leaving frequency and causality uncertain. The sensible response is neither panic nor denial: verify the device and operator, insist on anatomy-led planning and photographs, and have persistent hollowing, burns or neurological symptoms examined rather than managed through social media.